Role of genetic factors in development and progression of non-Hodgkin's lymphomas

Central European Journal of Public Health

Volumn 9, Issue 2, 2001, Pages 74-78

  Soucek P ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

Biotransformation; Lymphomas; Oncogenes; Suppressors; Tumor

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; GLUTATHIONE TRANSFERASE;

ARTICLE; BIOTRANSFORMATION; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; DISEASE COURSE; ENVIRONMENTAL FACTOR; EXON; GENETIC PREDISPOSITION; HEREDITY; HISTOPATHOLOGY; HUMAN; INTRON; LYMPHOPROLIFERATIVE DISEASE; MUTATION; NONHODGKIN LYMPHOMA; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PUBLIC HEALTH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

BIOTRANSFORMATION; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; CZECH REPUBLIC; GENES, TUMOR SUPPRESSOR; GENOTYPE; HUMANS; LYMPHOMA, NON-HODGKIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0034972546     PISSN: 12107778     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Inactivating mutations and overexpression of BCL-10, a caspase recruitment domain (CARD)-containing gene in MALT lymphoma with t(1;14)(p22;q32)
2. Recent advances in the molecular pathogenesis of lymphomas
3. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21
4. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
5. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice
6. LAZ3 rearrangements in non-Hodgkin's lymphoma: Correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients
7. Frequent mutation of the 5′-noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas
8. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma
9. Bcl-6 protein expression by follicle center lymphomas
10. Mutation of the 5′-noncoding region of the BCL-6 gene in low-grade gastric lymphoma of the mucosa-associated lymphoid tissue
11. Mutation analysis of the 5′ noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: Evidence for recurrent mutations and intraclonal heterogeneity
12. Genetic abnormalities in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
13. Progression from lymphoid hyperplasia to high-grade lymphoma in mice transgenic for the t(14;18)
14. Concurrent alterations at 3q27, 8q24 and 18q21 in B-cell lymphomas
15. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene
16. Loss of p53 function through PAX-mediated transcriptional repression
17. Multiple recurrent genomic defects in follicular lymphoma. A model for cancer
18. Detection of the second t(14;18) breakpoint cluster region in human follicular lymphomas
19. Expression of Bcl-2 proto-oncogene rescues PC12 cells from death caused by withdrawal of trophic support
20. Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress
21. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
22. p53: The ultimate tumor suppressor gene?
23. Replication error phenotype and p53 gene mutation in lymphomas of mucosa-associated lymphoid tissue
24. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas
25. Alterations of the retinoblastoma, a susceptibility gene in chronic lymphocytic leukemia
26. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression
27. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma
28. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series
29. Microsatellite instability in lymphoid leukemia and lymphoma cell lines but not in myeloid leukemia cell lines
30. Frequent clonal loss of heterozygosity but scarcity of microsatellite instability at chromosomal breakpoint cluster regions in adult leukemias
31. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis
32. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome
33. The hMre 11/hRad50 protein complex and Nijmegen breakage syndrome: Linkage of double-strand break repair to the cellular DNA damage response
34. The RAD52 epistasis group in mammalian double strand break repair
35. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins
36. Positional cloning of the gene for Nijmegen breakage syndrome
37. Human cytochrome P450 enzymes
38. Diagnosis of polymorphism in carcinogen-activating and inactivating enzymes and cancer susceptibility - A review
39. Association of cigarette smoking and CYP1A1 polymorphism with adenocarcinoma of the lung by grades of differentiation
40. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphism in a Japanese population
41. CYP1A1 genetic polymorphism and in situ colorectal cancer
42. Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence
43. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: Studies in upper aerodigestive tract cancers
44. A CYP1A1 restriction fragment length polymorphism is associated with cancer in African-American woman
45. Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects
46. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene
47. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer
48. Combined genetic polymorphism and risk for development of lung cancer
49. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer in relation to p53 gene mutation
50. Association between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer
51. Cytochrome P4502E1 genetic polymorphism and risk of nasopharyngeal carcinoma: Results from a case-control study conducted in Taiwan
52. Mammalian epoxide hydrases: Inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds
53. Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants
54. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema
55. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer
56. Genetic metabolic polymorphisms and the risk of cancer, a review of the literature
57. Human glutathione S-transferase Theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism
58. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
59. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility
60. Isolation of a cDNA clone and localization of the human glutathione S-transferase 3 genes to chromosome band 11q13 and 12q13-14
61. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties
62. Association between glutathione S-transferase π genetic polymorphisms and oral cancer risk
63. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk
64. Metabolic polymorphisms and susceptibility to cancer
65. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias
66. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms